Midatech Pharma Plc Market cap
What is the Market cap of Midatech Pharma Plc?
The Market cap of Midatech Pharma Plc is $1.63M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on LSE compared to Midatech Pharma Plc
What does Midatech Pharma Plc do?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Companies with market cap similar to Midatech Pharma Plc
- Kisses from Italy has Market cap of $1.63M
- ADM plc has Market cap of $1.63M
- Killi has Market cap of $1.63M
- ArcPacific Resources has Market cap of $1.63M
- Westcore has Market cap of $1.63M
- SNP Schneider-Neureither & Partner SE has Market cap of $1.63M
- Midatech Pharma Plc has Market cap of $1.63M
- Therapix Biosciences has Market cap of $1.63M
- Enea AB (publ) has Market cap of $1.64M
- VIP Gloves has Market cap of $1.64M
- Aphelion Capital has Market cap of $1.64M
- CE Brands has Market cap of $1.64M
- Sky Gold has Market cap of $1.64M